Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV

J Acquir Immune Defic Syndr. 2023 Jan 1;92(1):e3-e6. doi: 10.1097/QAI.0000000000003112.
No abstract available

MeSH terms

  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • HIV Infections* / drug therapy
  • Humans
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines